Clarivate Plc (NYSE:CLVT) announced on November 12, 2026, the expiration and final results of cash tender offers by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, to purchase its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, with $533,000,000 total aggregate principal amount accepted for purchase.

Key Highlights

  • Total accepted: $533,000,000 aggregate principal amount of notes accepted across both series, following the company's exercise of its right to increase the amount sought by 2% of the outstanding aggregate principal amount of each series.
  • 2028 Notes results: $611,502,000 aggregate principal amount tendered; $415,000,000 accepted at a proration factor of approximately 67.9%, at a total consideration of $979.08 per $1,000 principal amount.
  • 2029 Notes results: $259,297,000 aggregate principal amount tendered; $118,000,000 accepted at a proration factor of approximately 45.5%, at a total consideration of $928.75 per $1,000 principal amount.
  • Offers expired: At 5:00 p.m., New York City time, on November 10, 2026, with all conditions satisfied or waived on or prior to that date.
  • Settlement date: November 13, 2026, on which holders whose notes were accepted will also receive an accrued coupon payment.
  • Outstanding prior to tender: $750,000,000 for the 2028 Notes and $900,000,000 for the 2029 Notes.

Clarivate Science Holdings Tender Offer Final Results: Both Series Prorated

According to the filing, Clarivate Science Holdings Corporation, a wholly-owned subsidiary of Clarivate Plc (NYSE:CLVT), conducted cash tender offers to purchase up to $400,000,000 aggregate principal amount of its 3.875% Senior Secured Notes due 2028 and up to $100,000,000 aggregate principal amount of its 4.875% Senior Notes due 2029. The company disclosed that it exercised its right to increase each series cap by 2% of the outstanding aggregate principal amount of each series, raising the final 2028 Notes cap to $415,000,000 and the final 2029 Notes cap to $118,000,000.

The filing reports that the 2028 Notes drew $611,502,000 in tenders against $750,000,000 outstanding prior to the offer, with $415,000,000 accepted at a proration factor of approximately 67.9% and a total consideration of $979.08 per $1,000 principal amount. The 2029 Notes, with $900,000,000 outstanding prior to the offer, drew $259,297,000 in tenders, with $118,000,000 accepted at a proration factor of approximately 45.5% and a total consideration of $928.75 per $1,000 principal amount. The 2028 Notes total consideration was determined at 2:00 p.m., New York City time, on November 10, 2026, as described in the Tender Offer Documents.

The filing states that all conditions to the offers were satisfied or waived on or prior to the expiration date of November 10, 2026. Settlement is scheduled for November 13, 2026, at which time accepted holders will also receive an accrued coupon payment. Notes validly tendered but not accepted for purchase will be returned to tendering holders. The filing notes that the forward-looking statements it contains are subject to risks and uncertainties described in the company's Form 10-K and other regulatory filings, and the company does not undertake any obligation to update such statements except as required by applicable securities laws.

What Was Disclosed

Clarivate Science Holdings Corporation disclosed the expiration and final results of its cash tender offers for two series of notes, with $533,000,000 total aggregate principal amount accepted, settlement set for November 13, 2026, and proration applied to both series.